(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

ID: ALA5268162

Chembl Id: CHEMBL5268162

Max Phase: Preclinical

Molecular Formula: C22H22F3N7O3

Molecular Weight: 489.46

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ncn(-c2nc3c(C(=O)N[C@@H](c4ccc(OC(F)(F)F)cc4)C(C)(C)O)cnn3cc2C)n1

Standard InChI:  InChI=1S/C22H22F3N7O3/c1-12-10-31-19(29-18(12)32-11-26-13(2)30-32)16(9-27-31)20(33)28-17(21(3,4)34)14-5-7-15(8-6-14)35-22(23,24)25/h5-11,17,34H,1-4H3,(H,28,33)/t17-/m0/s1

Standard InChI Key:  HXMZXPQNCNEBPD-KRWDZBQOSA-N

Alternative Forms

  1. Parent:

    ALA5268162

    ---

Associated Targets(Human)

PDE2A Tclin Phosphodiesterase 2A (1799 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 489.46Molecular Weight (Monoisotopic): 489.1736AlogP: 3.07#Rotatable Bonds: 6
Polar Surface Area: 119.46Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.68CX Basic pKa: 1.28CX LogP: 3.96CX LogD: 3.96
Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.43Np Likeness Score: -1.35

References

1. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE..  (2021)  The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,  212  [PMID:33412421] [10.1016/j.ejmech.2020.113123]

Source